# OnCo record orm-6151 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/orm-6151/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "orm-6151" ;
  schema:name "ORM-6151 (BMS-986497)"@en ;
  schema:alternateName "ORM-6151"@en, "BMS-986497"@en ;
  schema:description "ORM-6151 (BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/orm-6151/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06419634>, <https://v.daum.net/v/20260919074351390>, <https://clinicaltrials.gov/search?intr=ORM-6151> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Degrader-antibody conjugate" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:targets <https://onco.cc/targets/cd33/> ;
  onco:companies <https://onco.cc/companies/orum-therapeutics/>, <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct06419634/> .